This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-17 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
The earliest cultures have used sugar as a preservative, and it was commonplace to store fruit in honey. "Sugar tends to draw water from the microbes (plasmolysis). This process leaves the microbial cells dehydrated, thus killing them. In this way, the food will remain safe from microbial spoilage." In northern climates without sufficient sun to dry foods, preserves are made by heating the fruit with sugar. Sugar is used to preserve fruits, either in an antimicrobial syrup with fruit such as apples, pears, peaches, apricots, and plums, or in crystallized form where the preserved material is cooked in sugar to the point of crystallization and the resultant product is then stored dry. The latter method is used for the skins of citrus fruit (candied peel), angelica, and ginger.
Informed consent approaches include conversations between the medical provider and person seeking care on the details of risks and outcomes, current understandings of scientific research, and how the provider can best assist the person in making decisions. Local standards of care exist in many countries, with most local standards being based on the WPATH standards, with some minor exceptions.
Morgan State began playing football in 1898, 31 years after the school was founded. The Bears have won three MEAC Championships (1976, 1979 and 2014). Their last Division I-AA/FCS playoffs appearance was in 2014. Fifty-three former Morgan players have gone on to play professional football. Former Morgan Bears Len Ford, Leroy Kelly, Willie Lanier and Rosey Brown are members of the Pro Football Hall of Fame in Canton, Ohio.
Pepstatins – N-acylated oligopeptides isolated from culture filtrates of Actinomycetes, which act specifically to inhibit acid proteases such as pepsin and renin. Peptide T – N-(N-(N(2)-(N-(N-(N-(N-D-Alanyl L-seryl)-L-threonyl)-L-threonyl) L-threonyl)-L-asparaginyl)-L-tyrosyl) L-threonine. Octapeptide sharing sequence homology with HIV envelope protein gp120. It may be useful as antiviral agent in AIDS therapy. The core pentapeptide sequence, TTNYT, consisting of amino acids 4-8 in peptide T, is the HIV envelope sequence required for attachment to the CD4 receptor. Phalloidin – A very toxic polypeptide isolated mainly from Amanita phalloides (Agaricaceae) or death cap; causes fatal liver, kidney and CNS damage in mushroom poisoning; used in the study of liver damage. Teprotide – A human-made nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is exactly the same as the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and angiotensin I and has been proposed as an antihypertensive agent. Tuftsin – N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide manufactured in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule. Halovir
Sources: en.wikipedia.org
== Structure == The ITGA2 gene is located on chromosome 5q11.2 and encodes the integrin alpha-2 (CD49b) protein. This is a type I transmembrane Glycoprotein that belongs to the integrin alpha chain family. The mature α2 subunit associates non-covalently with the β1 integrin subunit to form the α2β1 integrin receptor. This is a major collagen-binding integrin in vertebrates. Integrin α2 is an integrin alpha subunit, so it is made of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. The extracellular region contains an inserted (I) domain, or the αI domain. This is responsible for recognizing and binding collagen molecules within the extracellular matrix. Binding to collagen needs divalent cations such as magnesium (Mg2+) and manganese (Mn2+). This stabilizes the ligand-binding site and regulates receptor affinity. The α2β1 integrin has inactive and active conformations with different affinity for extracellular ligand. Intracellular signaling may lead to conformational changes of the integrin and increase the affinity to ligands (inside-out signaling), whereas ligand binding initiates signaling pathways that influence cell adhesion, migration, proliferation, and survival (outside-in signaling).
=== Periodontal === Periodontal EDS (pEDS) is an autosomal-dominant disorder characterized by four major criteria of severe and intractable periodontitis of early-onset (childhood or adolescence), lack of attached gingiva, pretibial plaques, and family history of a first-degree relative who meets clinical criteria. Eight minor criteria may also contribute to the diagnosis of pEDS. Molecular testing may reveal mutations in C1R or C1S genes affecting the C1r protein.
== Alternatives to medication == Cognitive behavioral therapy (CBT) is an effective treatment for panic disorder, social anxiety disorder, generalized anxiety disorder, and obsessive–compulsive disorder, while exposure therapy is the recommended treatment for anxiety related phobias. Healthcare providers can guide those with anxiety disorder by referring them to self-help resources. Sometimes medication is combined with psychotherapy but research has not found a benefit of combined pharmacotherapy and psychotherapy versus monotherapy. If CBT is found ineffective, both the Canadian and American medical associations then suggest the use of medication.
Angiotensin II stimulates the release of aldosterone from the adrenal gland, causing a decrease in electrolyte and water retention, ultimately increasing water excretion and decreasing blood volume and pressure. Like propranolol and pindolol, it is a serotonin 5-HT1A and 5-HT1B receptor antagonist; this discovery by several groups in the 1980s generated excitement among those doing research on the serotonin system as such antagonists were rare at that time.
Scientists develop a quantum experiment allowing the observation of a kind of theoretical wormhole in a SYK "baby" physical model which some, but not all, consider potentially useful for the development of quantum gravity theories.
Sources: en.wikipedia.org
=== Mentor === Hodgkin's mentor Professor John Desmond Bernal greatly influenced her life: scientifically, politically, and personally. Bernal was a key scientific adviser to the UK government during the Second World War. He was also an open and vocal member of the Communist Party and a faithful supporter of the Soviet regime until its invasion of Hungary in 1956. He was a chemist who believed in equal opportunity for women. In his laboratory, Hodgkin extended work that he began on biological molecules including sterols. She helped him to make the first X-ray diffraction studies of pepsin and crystalline protein. Hodgkin always referred to him as "Sage". They were lovers before she met Thomas Hodgkin. The marriages of both Dorothy and Bernal were unconventional by the standards of the present and of those days.
=== Features that promote de novo gene birth === Its also of interest to compare features of recently emerged de novo genes to the pool of non-genic ORFs from which they emerge. Theoretical modeling has shown that such differences are the product both of selection for features that increase the likelihood of functionalization, and of neutral evolutionary forces that influence allelic turnover. In budding yeast, systematic deletion and overexpression assays of newly emerged ORFs found that overexpression is enriched for fitness benefits, and that adaptive emerging sequences are biased toward encoding transmembrane domains from thymine-rich intergenic regions. One proposed route to de novo membrane proteins is that poly-A–rich sequences can generate hydrophobic ORFs that are predicted to form transmembrane helices. Across Saccharomycotina yeasts, intergenic regions show widespread enrichment for putative transmembrane-domain encoding potential, and this enrichment (rather than raw hydrophobicity alone) correlates with the abundance of transmembrane domains in evolutionarily young genes. Laboratory studies comparing young de novo proteins to matched unevolved random-sequence proteins found broadly similar predicted biophysical-property distributions, but moderately higher in vitro solubility for de novo proteins (further increased by the DnaK chaperone system). High-throughput sorting of thousands of putative human de novo sORF-encoded proteins by structural compactness showed that older candidates are, on average, more compact and less disordered than younger ones.
As a mucous connective tissue, it is rich in proteoglycans, and protects and insulates umbilical blood vessels. Wharton's jelly, when exposed to temperature changes, collapses structures within the umbilical cord and thus provides a physiological clamping of the cord, typically three minutes after birth.
Erythromycin, ketoconazole and cyclosporine are CYP3A4 inhibitors and therefore inhibit the metabolic pathway of docetaxel. When used with anticonvulsants, which induce CYP3A4, an increased dose of docetaxel may be required. Pre-treatment with corticosteroids has been used to decrease hypersensitivity reactions and oedema in response to docetaxel and has shown no effect on the pharmacokinetics of docetaxel. The efficacy of docetaxel was improved by treatment with oral capecitabine, and after more than 27 months follow-up the survival benefit has been confirmed. Doxorubicin was combined with docetaxel in one study of 24 patients and resulted in an increased AUC of docetaxel by 50 to 70%, indicating doxorubicin may affect the disposition of docetaxel. Etoposide has also been shown to decrease docetaxel clearance, though patient numbers for this observation have been low. Prednisone given with docetaxel led to improved survival, quality of life and pain management in patients with hormone-refractory prostate cancer.
Charles Miller Metzner (1931), judge on the United States District Court for the Southern District of New York and the Temporary Emergency Court of Appeals Lawrence E. Walsh (1932), independent counsel in the Iran-Contra affair; 4th United States Deputy Attorney General William Golub (1934), lawyer and advisor to Governor Nelson Rockefeller Harold Leventhal (1934), judge on the United States Court of Appeals for the District of Columbia Circuit John Slate (1935), lawyer and name partner of Skadden Arps Slate Meagher & Flom Daniel Mortimer Friedman (1937), judge of the United States Court of Appeals for the Federal Circuit, last chief judge of the United States Court of Claims, and acting solicitor general of the United States Wilfred Feinberg (1940), judge of the United States Court of Appeals for the Second Circuit Hugh H. Bownes (1941), judge of the United States Court of Appeals for the First Circuit Richard Kuh (1941), New York County district attorney and prosecutor of Lenny Bruce for obscenity Leonard I. Garth (1942), senior judge on the United States Court of Appeals for the Third Circuit Charles L. Brieant (1944), judge of the United States District Court for the Southern District of New York Jack Greenberg (1945), civil rights lawyer who argued the Brown v. Board of Education case before the United States Supreme Court Roy Cohn (1946), attorney and counsel to Sen. Joseph McCarthy Arthur Lazarus Jr. (1947), American Indian rights lawyer, argued United States v.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.